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The epidermal growth factor receptor (EGFr) is considered a major target for treatment of colorectal cancer (CRC). We found a
mean EGFr content significantly lower but more activated in colonic neoplastic tissue than in paired normal mucosa. Phosphorylated
(pY1068) EGFr detection in CRC may be a better tool than EGFr detection to select patients for targeted therapies.
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Epidermal growth factor receptor (EGFr) plays a pivotal role in
regulating epithelial proliferation, differentiation and survival.
Aberrant regulation of EGFr signalling has been implicated in the
development and progression of several different solid tumours
(Rubin Grandis et al, 1996; Rusch et al, 1997; Goldstein and
Armin, 2001). Colorectal cancer (CRC) is considered a tumour
showing EGFr overexpression, but EGFr expression ranges
between 25 and 75% (Salomon et al, 1995; Goldstein and Armin,
2001). The discrepancy in this range could be due to several
factors. The first is related to EGFr detection. The most popular
method of EGFr determination is immunohistochemistry (IHC)
that per se does not provide for reliable quantitative analysis, and
standardised techniques and scoring systems are lacking (Dei Tos
and Ellis, 2005). The second factor is related to possible nonuni-
form EGFr expression within the tumour area (Goldstein and
Armin, 2001). In addition, most studies are confined to neoplastic
tissue without normalisation to the corresponding normal mucosa.
Nevertheless, some IHC studies measuring EGFr expression both
in neoplastic tissue and paired normal colonic mucosa reported a
similar EGFr content in the two compartments (Moorghen et al,
1990; Maurer et al, 1998). These factors could be responsible
for the lack of comparable results in literature and the lack
of correlation between EGFr expression and the clinical activity
of EGFr inhibitors in humans (Cunningham et al, 2004; Chung
et al, 2005).
The aim of the present study was to shed more light on EGFr
expression in CRC, evaluating total and activated (pY1068) EGFr
and mRNA content on neoplastic tissue and paired normal mucosa
using two quantitative techniques (ELISA and real-time PCR).
MATERIALS AND METHODS
Patients and tissues
Thirty-nine patients (21 men and 18 women) surgically treated for
sporadic CRC were enrolled in the study. The clinical and
pathological parameters are summarised in Table 1. Tissue
samples were collected from the primary tumour and from
mucosa with a roughly normal appearance more than 25cm from
the lesion. Neoplastic tissue was quickly frozen in liquid nitrogen
and stored at  801C until use. Normal mucosa was split into two
blocks, one frozen and stored immediately and the other processed
for histological diagnosis to exclude pathological lesions.
Protein extraction and ELISA quantification of total and
activated (pY1068) EGFr
Frozen tissues were homogenised using lysis buffer (50mM Tris pH
7.4, 150mM NaCl, 2mM MgCl2, 1% Triton X-100, 10% glycerol,
2m M EGTA, 1mM DTT) containing protease inhibitors (10mgml
 1
aprotinin and leupeptin, 5mgml
 1 pepstatin, 1mM PMSF) and
phosphatase inhibitors (50mM NaF, 10mM Na4P2O7,1m M Na3VO4,
3m M H2O2). Homogenates were centrifuged at 13000g for 15min
at 41C, and supernatants were stored at  801C until analysis.
The concentration of total and pY1068 EGFr was assessed using
ELISA kits purchased from Biosource International Inc. (Camar-
illo, CA, USA). Protein lysates from A431 and SW620 cell lines
were used as positive and negative controls, respectively, to verify
the specificity of the EGFr ELISA assays.
Relative activated (pY1068) EGFr was defined as pY1068/total EGFr.
RNA extraction and real-time PCR quantification of EGFr
Total RNA was isolated using TRIzol Reagent (Invitrogen Life
Technologies, Carlsbad, CA, USA) and reverse transcribed using
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sSuperscript II (Invitrogen Life Technologies) with oligo-dT
primers, according to the manufacturer’s guidelines.
Gene-specific primers and TaqMan probes (Table 2) were
designed with the Beacon Designer 2.00 Software (Premier Biosoft
International, Palo Alto, CA, USA) and real-time PCR was
performed using an iCycler apparatus (Bio-Rad Laboratories,
Hercules, CA, USA). The cycle numbers were recorded when the
accumulated PCR products crossed an arbitrary threshold (CT or
threshold cycle) and CT values were used to calculate the
expression levels of EGFr relative to the internal reference b-actin.
Statistical analysis
Statistical calculations were performed using StatView 5.0 statis-
tical software (SAS Institute Inc., Cary NC, USA). For all analyses, a
P-value of less than 0.05 was considered significant. Values were
given as mean7s.e.
The paired t-test was used to detect differences in total and
relative activated (pY1068) EGFr and mRNA mean values between
normal and neoplastic tissue. Associations between these variables
were assessed by the Spearman rank test and regression analysis
was performed. The relationship with clinicopathologic parameters
was explored using the unpaired t-test.
RESULTS
Evaluation of total and activated (pY1068) EGFr by ELISA
Total and activated (pY1068) EGFr levels were determined in 39
paired samples. Mean total EGFr protein content was significantly
higher in normal mucosa than in neoplastic tissue ((260.8720.3)
vs (120.5714.7)fmol EGFrmg
 1 of total protein) (Figure 1A).
According to Spearman’s rank test, total EGFr expression levels
showed an association between normal mucosa and the respective
neoplastic tissue (R¼0.49; P¼0.004). This relationship was
visualised using scatterplot graphic analysis (Figure 1C). Mean
relative activated (pY1068) EGFr content was significantly higher
in neoplastic tissue than in normal mucosa ((1.10370.387) vs
(0.12970.019)Ufmol
 1 EGFr).
Evaluation of EGFr mRNA expression by real-time PCR
EGFr mRNA content was determined in 39 paired samples. Mean
EGFr mRNA content was significantly higher in normal mucosa
than in neoplastic tissue ((10.771.6) 10
 3 vs (7.871.1) 10
 3)
(Figure 1B). According to Spearman’s rank test, EGFr mRNA
expression showed an association between normal mucosa and the
respective neoplastic tissue (R¼0.65; Po0.0001). This relationship
was visualised using scatterplot graphic analysis (Figure 1D).
Regression analysis was also performed (Po0.0001).
Correlation with clinicopathologic parameters
No association was found between total or relative activated
(pY1068) EGFr or mRNA content in neoplastic tissue and normal
mucosa and sex, tumour location, histological grading and stage.
DISCUSSION
We studied total and activated (pY1068) EGFr and mRNA content in
neoplastic tissue and paired normal mucosa samples from 39 CRC
patients using two quantitative techniques. Three main results emerged
from the study. Firstly, both EGFr protein and mRNA content varied
widely in both neoplastic tissue and normal mucosa in our CRC
patients, in agreement with IHC studies (Salomon et al, 1995; Goldstein
and Armin, 2001). Secondly, EGFr expression in the apparently normal
colorectal mucosa of our CRC patients supports the idea that EGFr
expression may not be exclusive to CRC. In fact, normalising EGFr
protein content in neoplastic tissue vs normal mucosa did not disclose
EGFr overexpression. In addition, an association was found for EGFr
protein or mRNA content in neoplastic tissue and normal mucosa
from the same patient. Thirdly, in neoplastic tissue EGFr is more
activated than in paired normal mucosa.
These results have certain biological and clinical implications.
The fact that the mean EGFr content is higher in normal mucosa
than in neoplastic tissue, both for protein and mRNA determina-
tion, does not exclude a role for EGFr in the carcinogenesis of CRC.
Epidermal growth factor receptor signalling in the maintenance of
carcinomas during intestinal tumorigenesis has been found in
animal experiments (Roberts et al, 2002). In our study, the inverse
relationship between EGFr expression and activity, demonstrated
so far in CRC cell lines (Keese et al, 2005), supports the hypothesis
that activated EGFr has a role in CRC.
Table 1 Demographic and pathological characteristics of the CRC
patients
Patients
Characteristic No. %
Age (years)
Mean 69.271.5
Range 46–84
Sex
Female 18 46.2
Male 21 53.8
Lesion site
Right colon 15 38.5
Left colon 24 61.5
Tumour diameter (mm)
Mean 47.472.5
Range 24–100
Histological grading
Poorly differentiated 6 15.4
Moderately differentiated 31 79.5
Well differentiated 2 5.1
Pathological staging
Stage II 18 46.2
Stage III 19 48.7
Stage IV 2 5.1
CRC¼colorectal cancer.
Table 2 Primers and Taqman probes
Gene GenBank Accession No. Forward primer (50–30) Reverse primer (50 –30) Taqman probe (50–30)
EGFr NM_005228 TTCCTCCCAGTGCCTGAAT GGGCTGGACAGTGTTGAGAT CGCCCAGCAGAGACCCACACTACC
b-Actin NM_001101 CGGCCAGGTCATCACCATTG TGGAGTTGAAGGTAGTTTCGTGG TGCCACAGGACTCCATGCCCAGG
EGFr¼epidermal growth factor receptor.
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most importantly, the EGFr content is frequently lower but more
activated in cancer tissue than in paired normal mucosa.
Epidermal growth factor receptor activity may be considered a
better indicator than EGFr content when selecting expected
responders to targeted therapy. This would, in part, explain the
modest results observed in clinical practice when specific
antibodies (i.e. Cetuximab) are combined with chemotherapy for
CRC patients with IHC-positive tumors (Cunningham et al, 2004;
Chung et al, 2005). The activity of specific monoclonal antibodies
on apparently normal colorectal mucosa overexpressing EGFr, and
the crosstalking of different biological pathways leading to cancer
growth should be topics for preclinical research. Some studies
currently in progress on these issues are expected to yield more
data for a more correct clinical use of the so-called targeted
therapies (Pantaleo et al, 2006).
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Figure 1 EGFr content in normal mucosa and in neoplastic tissue. Paired protein (A) and mRNA (B) samples are connected by lines. Box-plot graphic
analyses are also shown. Scatterplot graphic analysis for EGFr protein (C) and mRNA (D) content are reported. Each dot represents EGFr protein or mRNA
content in normal mucosa and neoplastic tissue of the same patient.
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